ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2017

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.

Jürgen Harreiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.